BioLineRx Ltd. (BLRX)
 NASDAQ: BLRX · Real-Time Price · USD
 3.500
 0.00 (0.00%)
  At close: Oct 30, 2025, 4:00 PM EDT
3.410
 -0.090 (-2.57%)
  After-hours: Oct 30, 2025, 6:21 PM EDT
BioLineRx Revenue
BioLineRx had revenue of $304.00K in the quarter ending June 30, 2025, a decrease of -94.36%. This brings the company's revenue in the last twelve months to $17.25M, up 1.19% year-over-year. In the year 2024, BioLineRx had annual revenue of $28.94M with 502.92% growth.
Revenue (ttm) 
 $17.25M
Revenue Growth 
 +1.19%
P/S Ratio 
 0.93
Revenue / Employee 
 $616,107
Employees 
 28
Market Cap 
16.05M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 28.94M | 24.14M | 502.92% | 
| Dec 31, 2023 | 4.80M | - | - | 
| Dec 31, 2022 | - | - | - | 
| Dec 31, 2021 | - | - | - | 
| Dec 31, 2020 | - | - | - | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 63.62B | 
| Eli Lilly and Company | 59.42B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Novo Nordisk | 49.11B | 
BLRX News
- 4 weeks ago - BioLineRx Ltd. - Special Call - Seeking Alpha
- 4 weeks ago - BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers - PRNewsWire
- 2 months ago - BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 3 months ago - BioLineRx to Report Second Quarter 2025 Results on August 14, 2025 - PRNewsWire
- 5 months ago - Why Is Nano-Cap BioLineRx Stock Surging On Friday? - Benzinga
- 5 months ago - BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting - PRNewsWire
- 5 months ago - BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call Transcript - Seeking Alpha